ClinicalTrials.gg
RecruitingNCT07311083BallastImmunUpdated Oct 27, 2026

Feasibility of a Lifestyle Intervention for Women With Triple-negative Breast Cancer Under Neoadjuvant Immunotherapy

An interventional study of switching to a high-fibre diet and official dietary recommendations in Microbiome, sponsored by Kliniken Essen-Mitte. Recruiting at 1 site in Germany. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Kliniken Essen-Mitte · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Oct 27, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Study summary

Triple-negative breast cancer (TNBC) is considered a tumor with a high risk of recurrence and metastasis and requires aggressive systemic therapy combining immunotherapy and chemotherapy. If the therapy leads to complete remission (pCR), this is prognostically beneficial for patients.

Studies demonstrating the influence of the microbiome on the development of cancer and on the efficacy and toxicity of immunotherapy and chemotherapy underscore the potential of targeted nutritional interventions. Current data from microbiome research indicate that a high-fiber, gut-healthy diet modulates the microbiota in such a way that the response to and toxicity of immunotherapy and chemotherapy could be improved.

The aim of this project is to translate these findings into clinical care. The study will investigate whether an online integrative oncology group training program with mind-body elements supports and is feasible for the implementation of a high-fiber diet in patients with TNBC undergoing neoadjuvant immunotherapy and chemotherapy. The program will be compared with a control group that receives a flyer with nutritional recommendations. If the feasibility of this complementary medicine approach can be demonstrated, a confirmatory study is planned to investigate the expected effect on the pathological complete remission of TNBC.

Read the detailed description

This study examines a nutritional concept developed specifically for this study with regard to the implementation of a switch to a high-fibre diet in patients with TNBC undergoing neoadjuvant immunotherapy and chemotherapy. This nutritional concept is embedded in an online, integrative oncology group training programme with mind-body medicine elements to support the change in diet and its tolerability. This intervention is compared with a control group that receives standard care, i.e. a flyer and an educational training video with nutritional recommendations based on the guidelines of the German Nutrition Society (DGE).

The following criteria have been established to determine the feasibility of these two target levels:

  • Recruitment
  • Consent to participate and randomisation
  • Dropout rate
  • Implementation of the intervention (dietary change and acceptance/effect of mind-body elements)
  • Completeness of data collected for at least 80% of patients who complete the study

If the study proves feasible and demonstrates the viability of this integrative medical approach in women with TNBC undergoing neoadjuvant immunotherapy, a confirmatory intervention study with a larger sample size is planned. This study aims to contribute to expanding the current knowledge base and improving existing treatment options. The follow-up study aims to investigate the effects of the nutritional concept and the group training programme on the pCR of TNBC. It will analyse whether the nutritional concept and the group training programme enhance the response to immunotherapy and improve its tolerability in the study participants. The findings from this study will therefore be incorporated into the follow-up study, which will investigate the potential for an improved immune response to therapy and, at the same time, identify possible positive effects of the nutritional intervention on the side effect profile of immunotherapy. Furthermore, the design of the nutritional concept and/or the group training programme could be adapted for the follow-up study if the results are appropriate. The findings from both studies will then be transferred to clinical care, thereby optimising the current treatment options for TNBC patients and increasing their chances of recovery in the long term.

02

Conditions studied

  • Microbiome
03

In context

Lead sponsor

Kliniken Essen-Mitte is the lead sponsor of 18 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged 18-75
  • confirmed diagnosis of non- triple-negative breast cancer (TNM stage I-III) with planned chemotherapy and immunotherapy
  • Willingness to participate in the study and signed consent form

Exclusion criteria

Exclusion Criteria:

  • Advanced stage of disease with
  • Severe physical or psychopharmacologically treated psychiatric comorbidity that prevents a patient from participating in the study
  • Pregnancy
  • Participation in other clinical studies involving behavioral, psychological, or complementary medical interventions
  • A diet that is incompatible with a high-fiber diet, such as the ketogenic diet
  • Abuse of drugs and/or alcohol
  • Inability to complete the questionnaires independently
  • Colectomy
  • Gastrointestinal stenosis
  • Fructose intolerance
  • Histamine intolerance
  • Gluten intolerance
  • Ketogenic diet
  • Unwillingness to refrain from taking probiotics for the duration of the study
  • Eating disorders
  • No laptop and/or camera available to participate in the online group training program
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Switching to a high-fibre diet in patients with TNBC undergoing neoadjuvant immunotherapy and chemot

    Switching to a high-fibre diet is supported by multi-professional consultation hours, individual counselling and group sessions that combine mind-body medicine and nutritional therapy content.

    Other: switching to a high-fibre diet

  • Active comparator
    control group receives official dietary recommendations

    Control group receives standard care, i.e. a leaflet and an educational training video with dietary recommendations of the Deutsche Gesellschaft fuer Ernaehrung (DGE)

    Other: official dietary recommendations

Interventions

  • Otherswitching to a high-fibre diet

    The aim of the intervention is to support patients in implementing a high-fibre diet (20-30 g of fibre per day) before and during systemic therapy. A multi-professional team consisting of a specialist doctor, a qualified nutritionist and an MBM therapist ensures comprehensive support during lifestyle modification. While the nutritional counselling provides recommendations for optimising diet, the MBM intervention addresses behavioural factors such as motivation, self-efficacy expectations and dealing with barriers to action. In addition, the specialist provides advice on symptom management.

  • Otherofficial dietary recommendations

    providing official dietary recommendations and an educational training video based on these recommendations of the guidelines of the German Nutrition Society (DGE)

06

What researchers measure

Primary outcomes

  1. The primary target parameter is the feasibility of the planned study and the intervention.

    The feasibility criteria are defined in the following categories: Recruitment: * Recruitment is considered feasible if the required sample size of n = 60 patients can be recruited within 17 months. * Randomisation: Randomisation is considered feasible if at least 25% of potentially eligible patients agree to participate in the study * Dropout rate: A maximum dropout rate of 20% per group is considered proof of feasibility. * Intervention: The intervention is considered feasible if at least 80% of the patients who complete the study are able to implement the nutritional intervention according to protocol. Implementation according to protocol is defined as a fibre intake of at least 20 g/day and the consumption of fermented foods. Data collection: Data collection is considered feasible if complete data on the planned primary endpoint parameter of the planned confirmatory study, pCR, is available for at least 80% of the patients who complete the study.

    Time frame: from the enrolment to the end of treatment at 6.5 months

Secondary outcomes

  1. Course of therapy (pCR)

    Course of therapy in the sense of a complete response to systmatic therapy (= complete pathological remission)

    Time frame: 6 months after baseline

  2. Toxicity (CTCAE 6.0) including adverse events (AEs)

    adverse events

    Time frame: 6 months after baseline

  3. Fatty acid profile (stool sample analysis)

    Fatty acid profile

    Time frame: baseline and 6 months after baseline

  4. α-diversity and β-diversity of the microbiome (stool sample analysis)

    diversity of the microbiome

    Time frame: baseline and 6 months after baseline

  5. Body weight

    Body weight

    Time frame: baseline, 1 to 3 weeks after baseline (start of the chemotherapy), 3 months after baseline, 6 months after baseline

  6. Self-reported quality of life (FACT-B = Functional Assessment of Cancer Therapy - Breast)

    quality of life, ranges from 0 to 4, with lower scores indicating higher stress levels which means a lower quality of life

    Time frame: baseline, 1 to 3 weeks after baseline (start of the chemotherapy), 3 months after baseline, 6 months after baseline

  7. Self-reported fatigue (FACIT fatigue = Functional Assessment of Chronic Illness Therapy Fatgigue)

    Self-reported fatigue, scale from 0 to 4 with lower value indicating a greater fatigue. Two items are reversed.

    Time frame: baseline, 1 to 3 weeks after baseline (start of the chemotherapy), 3 months after baseline, 6 months after baseline

  8. Self-reported fiber intake (dietary records)

    Self-reported fiber intake

    Time frame: baseline, 1 to 3 weeks after baseline (start of the chemotherapy), 3 months after baseline, 6 months after baseline

  9. Self-reported tolerance of increased fiber intake (IBS-SSS = irritable bowel syndrome severity scoring system)

    Self-reported tolerance of increased fiber intake, symptoms are rated on a visual analog scale (VAS) from 0 to 100 points. 100 points indicate the most severe irritable bowel symptoms.

    Time frame: baseline, 1 to 3 weeks after baseline (start of the chemotherapy), 3 months after baseline, 6 months after baseline

  10. Adverse Events and Serious Adverse Events

    Adverse Events and Serious Adverse Events

    Time frame: baseline, 1 to 3 weeks after baseline (start of the chemotherapy), 3 months after baseline, 6 months after baseline

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Feb 2026 (actual). Primary completion is estimated for Jul 2027, 17 months after the start.

Primary completion moved once since we started tracking on Sep 25, 2026: Jul 2026 → Jul 2027, on Oct 27, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Dec 30, 2025
StartActual
Feb 1, 2026
Primary completionEst.
Jul 1, 2027was Jul 2026
CompletionEst.
Jul 1, 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 1, 2026→Jul 1, 2027
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Primary completion Jul 1, 2026→Jul 1, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07311083
Lead sponsor
Kliniken Essen-Mitte
Collaborators
Karl and Veronica Carstens Foundation
Responsible party
Sponsor
First posted
Dec 30, 2025
Start date
Feb 1, 2026
Primary completion
Jul 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Oct 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion